OCGN beat EPS expectations by 8.09%
Nov 22, 2024, 11:32 PM
0.83%
What does OCGN do
Ocugen is a biopharmaceutical company based in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases, including inherited retinal disorders. The company also develops inhalation-based vaccines for COVID-19 and seasonal flu.
Ocugen (OCGN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ocugen's actual EPS was -$0.05, beating the estimate of -$0.05 per share, resulting in a 8.09% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.